[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100651067":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":32,"locations":38,"responsibleParty":55,"collaborators":59,"id":66,"slug":67,"hasResults":68,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":26,"eligibilityCriteria":72,"healthyVolunteers":68,"sex":73,"minAge":74,"maxAge":75,"enrollmentInfo":76,"targetDuration":26,"studyType":79,"phases":80,"briefSummary":82,"conditions":83,"keywords":26,"overallStatus":87,"whyStopped":26,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":97},{"fullName":5,"class":6},"Nova Scotia Health Authority","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Placebo Medication","PLACEBO_COMPARATOR","Patients administered placebo medication for at least 6 months preoperatively",[13],"Behavioral: Behavioral + placebo",{"label":15,"type":16,"description":17,"interventionNames":18},"Study medication group","EXPERIMENTAL","Patients receive at least 6 months of study group medication preoperatively",[19],"Drug: GLP-1 Receptor Agonists + Behavioral modification",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","GLP-1 Receptor Agonists + Behavioral modification","At least 6 months of preoperative semaglutide and structured behavioural modification",[15],null,{"type":28,"name":29,"description":30,"armGroupLabels":31,"otherNames":26},"BEHAVIORAL","Behavioral + placebo","Structured behavioural modification - diet, exercise, counselling and placebo medication",[9],[33],{"name":34,"role":35,"phone":36,"phoneExt":26,"email":37},"Jhase Sniderman, MD, MSc, FRCSC, FAAOS","CONTACT","9029323130","jhase.sniderman@nshealth.ca",[39],{"facility":40,"status":26,"city":41,"state":42,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"Nova Scotia Health","Dartmouth","Nova Scotia","B2Y 2N5","Canada","CA",{"type":47,"coordinates":48},"Point",[49,50],-63.57719,44.67134,{"lat":50,"lon":49},[53],{"name":54,"role":35,"phone":36,"phoneExt":26,"email":37},"Jhase Sniderman, MD,MSc, FRSCS, FAAOS",{"type":56,"investigatorFullName":57,"investigatorTitle":58,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"PRINCIPAL_INVESTIGATOR","Jhase Sniderman","Orthopaedic Surgeon, MD, MSc, FRCSC, FAAOS",[60,62,64],{"name":61,"class":6},"Orthopaedic Innovation Centre",{"name":63,"class":6},"Dalhousie University",{"name":65,"class":6},"University of Manitoba","100651067","glp-1s-in-hip-and-knee-arthroplasty-100651067",false,"NCT07755085","GLP-1s in Hip and Knee Arthroplasty","Does the Preoperative Use of GLP-1 Agonists Change Outcomes in Patients Waiting for Total Hip and Knee Arthroplasty: A Pilot Randomized Control Trial","Inclusion Criteria:\n\n* Patients with a diagnosis of hip or knee arthritis and are a deemed candidate for THA or TKA by an orthopaedic surgeon\n* Diagnosis of BMI 35+ with an obesity-related health condition (Coronary vascular disease, previous stroke, type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, asthma) or BMI 40+\n* Patients must be between 18-90 years of age\n* Able to provide informed consent\n\nExclusion Criteria:\n\n* Cognitive impairment that precludes study participation and compliance\n* Patients unwilling to undergo smoking cessation prior to surgery\n* Patients currently taking biologic medications that suppress the immune system\n* Patients currently taking GLP-1 medications\n* Patients with a contraindication to GLP-1 medication","ALL","18 Years","90 Years",{"count":77,"type":78},100,"ESTIMATED","INTERVENTIONAL",[81],"PHASE4","The number of people living with hip and knee arthritis continues to grow. A large amount of these people are also overweight and diagnosed with obesity. Obesity leads to more stress on hip and knee joints, causing them to wear out sooner. This process is called arthritis. When arthritis gets worse, the joints often need to be replaced due to pain and poor mobility. Very heavy patients often have other health problems that can impair the ability to manage arthritis. Excess weight and health problems can change the way heavy patients recover after surgery, leading to a greater risk of complications. A new type of medicine might be able to improve how obese patients manage their hip and knee pain, as well as improve outcomes after surgery. This type of medicine is called a GLP-1. Investigators will study 2 groups, with one receiving the medicine while the other does not. The goal is to understand how these medications work in the time leading up to surgery and in the early postoperative recovery phase. If these medications help, it may improve the care of high risk obese patients.",[84,85,86],"Arthritis","Obesity & Overweight","GLP - 1","NOT_YET_RECRUITING","2026-08-07",{"date":90,"type":91},"2026-08-10","ACTUAL",{"date":93,"type":78},"2026-10-01",{"date":95,"type":78},"2028-12",{"name":5,"class":6},1]